These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 38768681)

  • 1. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
    Xu M; Li S
    Cancer Lett; 2024 Jul; 593():216969. PubMed ID: 38768681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
    Kirthiga Devi SS; Singh S; Joga R; Patil SY; Meghana Devi V; Chetan Dushantrao S; Dwivedi F; Kumar G; Kumar Jindal D; Singh C; Dhamija I; Grover P; Kumar S
    Eur J Pharm Biopharm; 2024 Jul; 200():114323. PubMed ID: 38754524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.
    Zhu Z; Jin Y; Zhou J; Chen F; Chen M; Gao Z; Hu L; Xuan J; Li X; Song Z; Guo X
    Mol Cancer; 2024 Jul; 23(1):146. PubMed ID: 39014460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications.
    Germanà E; Pepe L; Pizzimenti C; Ballato M; Pierconti F; Tuccari G; Ieni A; Giuffrè G; Fadda G; Fiorentino V; Martini M
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy.
    Han R; Rao X; Zhou H; Lu L
    Int J Nanomedicine; 2024; 19():4803-4834. PubMed ID: 38828205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.
    Jalili-Nik M; Soltani A; Mashkani B; Rafatpanah H; Hashemy SI
    Int Immunopharmacol; 2021 Sep; 98():107870. PubMed ID: 34153661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy.
    Yu L; Huang K; Liao Y; Wang L; Sethi G; Ma Z
    Cell Prolif; 2024 Aug; 57(8):e13644. PubMed ID: 38594879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.
    Liu Q; Guan Y; Li S
    Mol Cancer; 2024 Sep; 23(1):183. PubMed ID: 39223527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors.
    Han L; Meng Y; Jianguo Z
    Curr Cancer Drug Targets; 2024; 24(11):1104-1115. PubMed ID: 38318829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].
    Sheng J; Yu X; Li H; Fan Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):976-982. PubMed ID: 32773010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
    Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
    World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
    Munari E; Mariotti FR; Quatrini L; Bertoglio P; Tumino N; Vacca P; Eccher A; Ciompi F; Brunelli M; Martignoni G; Bogina G; Moretta L
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.